In this last study, 30% of patients received low-toxicity chemotherapy and the average age of these patients was 73 years, whereas the average age of the whole group was 77 years.
Dose delays or modifications were required for drug-related grade 3/4 toxicities; patients received lower doses when toxicity improved to grade 2 or better, but therapy was discontinued if recovery time was 3 weeks or longer.
For example, Price & Han (2011) show how Maximum Cumulative Ratio (MCR), the ratio of the cumulative toxicity received by an individual from exposure to multiple chemicals to the largest toxicity from a single chemical, can be used as part of the WHO/IPCS Tier 1 and Tier 2 assessments.
All patients with suspected serotonin toxicity received intravenous fentanyl continuously.
Conflicting reports have been received about the toxicity of QD [172, 173] in mammals even though CdSe QD is known to arrest the root growth of rice seedlings.
Group IIIA exposures have one chemical that is responsible for the majority of the toxicity received by a receptor and that chemical should be the focus of either refining the risk assessment or reducing exposure.
In arm A, all but one patient (toxicity) received the planned 3 cycles of bevacizumab.
Six metastatic patients, and one patient with localized disease who stopped chemotherapy due to severe toxicity, received craniospinal radiotherapy.
After discontinuation of the chemoradiotherapy, the two patients who showed the ALT elevation suspected as gemcitabine-related toxicity received chemoradiotherapy using 5-FU, and the other two patients underwent only supportive care.
Any individual demonstrating clinical signs and symptoms of vitamin D toxicity and/or an SAE related to the study protocol resulted in: 1) vitamin D3 supplementation discontinued, 2) responsible physician (PS) notified so the patient received treatment for toxicity (as above), 3) notification of the DSMB and Health Canada, and 4) patient participation in the study was discontinued.
